FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Federal Register

CDRH Testing Communications Info Collection

Federal Register notice: FDA seeks comments on an information collection entitled Testing Communications by FDAs Center for Devices and Radiological H...

latest-news-card-1
Federal Register

Measuring Growth/Pubertal Development Guide

Federal Register notice: FDA makes available a draft guidance entitled Measuring Growth and Evaluating Pubertal Development in Pediatric Clinical Tria...

latest-news-card-1
Federal Register

Guide on Cell/Tissue-based Products

Federal Register notice: FDA makes available a final guidance entitled Regulation of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT...

latest-news-card-1
Human Drugs

ICH Guide Aims to Reduce Rat Carcinogenic Studies: FDA

FDA releases a guidance, S1B(R1) Addendum to S1B Testing for Carcinogenicity of Pharmaceuticals; International Council for Harmonization; Guidance for...

latest-news-card-1
Medical Devices

FDA Revises EUAs for Covid Serial Testing

FDA revises the authorized uses and is requiring updates to product labeling regarding repeat (serial) testing for all currently authorized Covid-19 a...

latest-news-card-1
Federal Register

Special Protocol Assessment Information Collection

Federal Register notice: FDA seeks comments on an information collection extension entitled Special Protocol Assessment.

latest-news-card-1
Federal Register

Info Collection on BLA Procedures

Federal Register notice: FDA seeks comments on an information collection extension entitled Biologics License Applications Procedures and Requirements...

latest-news-card-1
Human Drugs

Measuring Growth and Evaluating Pubertal Development Guide

FDA posts a draft guidance on recommendations for measuring and recording growth, and evaluating pubertal development for evaluating safety in pediatr...

latest-news-card-1
Federal Register

Special Protocol Assessment Information Collection

Federal Register notice: FDA seeks comments on an information collection extension entitled Special Protocol Assessment.

latest-news-card-1
Human Drugs

BMS Reblozyl Meets Endpoint in Anemia Patients

Bristol Myers Squibb reports that its COMMANDS Phase 3 study evaluating Reblozyl (luspatercept-aamt) met its primary endpoint in first-line treatment ...